Skip to main content

Table 1 General characteristics of kidney transplant recipients

From: Prevalence of vancomycin-resistant Enterococcus fecal colonization among kidney transplant patients

Number of Patients 280 (100)
   Group 1 (less than 30 days after transplantation) 102 (36.4)
   Group 2 (1 to 6 months after transplantation) 73 (26)
   Group 3 (> 6 months after transplantation) 105 (37.5)
Gender  
   Male 163 (58.2)
Race  
   White 187 (66.7)
   Non-white 93 (33.2)
Primary renal disease  
   Indeterminate 137 (48.9)
   Hypertension 61 (21.7)
   Glomerulonephritis 44 (15.7)
   Diabetes Mellitus 11 (3.9)
   Others 27 (9.6)
Pre transplant treatment  
   Hemodialysis 262 (93.5)
   CAPD 12 (4.2)
   Conservative 6 (2.1)
Kidney donor  
   HLA I and II 160 (57.1)
   HLA III and deceased donor 120 (42.8)
Immunosuppressive drugs **  
   Mycophenolate mofetil 59 (33.1)
   OKT3/Thymoglobulin® 13 (7.3)
   Methylprednisolone pulse 58 (32.5)
Surgical reexploration 14 (5)
Post-transplantation dialysis 46 (16.4)
Serology  
   Hepatitis C virus 31 (11)
   Hepatitis B virus 7 (2.5)
Post-transplantation antimicrobial drugs ** 117 (65.7)
Vancomycin ** 11 (6.1)
Ganciclovir ** 18 (10.1)
  1. ** Immunosuppressive drugs, post-transplantation antimicrobial drugs, vancomycin and ganciclovir: just for groups 2 and 3.
  2. CAPD = chronic ambulatory peritoneal dialysis; HLA I = identical human leukocyte antigen;
  3. HLA II = haplo-identical human leukocyte antigen; HLA III = distinct human leukocyte antigen;
  4. Values are expressed as N (%).